PPARG and Other metabolic disease: This study identified three high potential conductive phytochemicals capable of binding to the active site of PPARγ.The set of compounds identified can lead to a therapeutic solution against DT2 by effectively targeting the function site of PPARγ.Rosiglitazone is a full agonist of the peroxisome proliferator-activated receptor gamma (PPARγ), and although it is effective intreating metabolic disorders, it has been associated with a higher risk of adverse effects compared to partial agonists.